STAT October 31, 2019
Kate Sheridan

When Laura Indolfi set out to launch a biotech in Boston, she had an idea — and little else. She had never run a company before. She had no practical experience in fundraising.

But she was undeterred. In 2014 she founded PanTher Therapeutics, with the goal of turning a postdoctoral side project into a bona-fide drug delivery company.

“I took a leap of faith,” she told STAT.

Through her five-year odyssey, Indolfi learned a fundamental lesson about the biotech world: who you know can be as important — or even more important — as what you want to do.

First, her “leap of faith’’ needed to be backed up with data. But soon, she needed to match it with cold,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Provider, Technology
Top 20 pharma companies by 2023 revenue
Regeneron launches $500m venture capital arm
STAT+: Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
Pharma Pulse 4/15/24: Human Oversight with AI in Clinical Research, The Health and Healthcare of Gen Xers
STAT+: Can investing in infectious disease pay off? Vir Biotechnology’s tightrope walk shows it’s a struggle

Share This Article